Several compelling evidence demonstrates that a novel tsRNA, tRF-Glu-CTC, contributes to the development of neovascular AMD by releasing inflammatory factors and inhibiting VASH1 to induce angiogenic phenotypes in endothelial cells. Here, VASH1 is linked to age-related macular degeneration.